PERSIST: A multicenter, randomized phase II trial of perioperative oxaliplatin and S-1 (SOX) with or without sintilimab in resectable locally advanced gastric/gastroesophageal junction cancer (GC/GEJC).Xuewei Ding, Han Liang, Mingzhi Cai et al.|Journal of Clinical Oncology|2023Cited by 30
Perioperative sintilimab combination with SOX for resectable locally advanced gastric/gastroesophageal junction cancer(GC/GEJC): Initial findings of a single-arm phase II trial.Xuewei Ding, Han Liang, Bin Li et al.|Journal of Clinical Oncology|2022Cited by 14
Intraperitoneal Chemotherapy Using Fluorouracil Implants Combined With Radical Resection and Postoperative Adjuvant Chemotherapy for Stage III Gastric Cancer: A Multi-Center, Randomized, Open-Label, Controlled Clinical StudyYan Xu, Huimian Xu, Rupeng Zhang et al.|Frontiers in Oncology|2021Cited by 7
CO-STAR: Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) combined with Nab-PTX, S-1 and apatinib for the first-line treatment of stage IV gastric cancer (GC).Qiang Xue, Han Liang, Baogui Wang et al.|Journal of Clinical Oncology|2021Cited by 6
[Analysis of clinicopathological characteristics and prognosis on 42 patients with primary gastric adenosquamous cell carcinoma].Bin Li, Han Liang, Lin Sun et al.|PubMed|2017Cited by 5